Effects of transdiagnostic group treatment for sleep disturbances in adult attention-deficit/hyperactivity disorders and autistic spectrum disorder: a pilot study.

"Declarations Conflict of interestThe authors declare no conflict of interest. However, I.O. has received grants from NEC Solution Innovators and personal fees from Otsuka Pharmaceutical, Merck Sharp & Dohme, Eisai, and Takeda Pharmaceuticals for projects unrelated to the submitted work. Y.T. has received lecture fees from Otsuka Pharmaceutical, Meiji Seika Pharma, Eli Lilly, Eisai, Mitsubishi Tanabe Pharma, MSD, and Yoshitomi Pharmaceutical, and research funding from Otsuka Pharmaceutical, Meiji Seika Pharma, MSD, and Eisai. Ethical approvalThis study was approved by the ethics committee of Institute of Neuropsychiatry. All participants provided written informed consent (Trial Registration No. UMIN000024461; umin.ac.jp/ctr). Conflict of interest The authors declare no conflict of interest. However, I.O. has received grants from NEC Solution Innovators and personal fees from Otsuka Pharmaceutical, Merck Sharp & Dohme, Eisai, and Takeda Pharmaceuticals for projects unrelated to the submitted work. Y.T. has received lecture fees from Otsuka Pharmaceutical, Meiji Seika Pharma, Eli Lilly, Eisai, Mitsubishi Tanabe Pharma, MSD, and Yoshitomi Pharmaceutical, and research funding from Otsuka Pharmaceutical, Meiji Seika Pharma, MSD, and Eisai."

"This work was partially supported by JSPS KAKENHI grant numbers 16K04388. Declarations: Conflict of interestThe authors declare no conflict of interest. However, I.O. has received grants from NEC Solution Innovators and personal fees from Otsuka Pharmaceutical, Merck Sharp & Dohme, Eisai, and Takeda Pharmaceuticals for projects unrelated to the submitted work. Y.T. has received lecture fees from Otsuka Pharmaceutical, Meiji Seika Pharma, Eli Lilly, Eisai, Mitsubishi Tanabe Pharma, MSD, and Yoshitomi Pharmaceutical, and research funding from Otsuka Pharmaceutical, Meiji Seika Pharma, MSD, and Eisai.: Ethical approvalThis study was approved by the ethics committee of Institute of Neuropsychiatry. All participants provided written informed consent (Trial Registration No. UMIN000024461; umin.ac.jp/ctr). Conflict of interest: The authors declare no conflict of interest. However, I.O. has received grants from NEC Solution Innovators and personal fees from Otsuka Pharmaceutical, Merck Sharp & Dohme, Eisai, and Takeda Pharmaceuticals for projects unrelated to the submitted work. Y.T. has received lecture fees from Otsuka Pharmaceutical, Meiji Seika Pharma, Eli Lilly, Eisai, Mitsubishi Tanabe Pharma, MSD, and Yoshitomi Pharmaceutical, and research funding from Otsuka Pharmaceutical, Meiji Seika Pharma, MSD, and Eisai."

"Declarations: Conflict of interestThe authors declare no conflict of interest. However, I.O. has received grants from NEC Solution Innovators and personal fees from Otsuka Pharmaceutical, Merck Sharp & Dohme, Eisai, and Takeda Pharmaceuticals for projects unrelated to the submitted work. Y.T. has received lecture fees from Otsuka Pharmaceutical, Meiji Seika Pharma, Eli Lilly, Eisai, Mitsubishi Tanabe Pharma, MSD, and Yoshitomi Pharmaceutical, and research funding from Otsuka Pharmaceutical, Meiji Seika Pharma, MSD, and Eisai.: Ethical approvalThis study was approved by the ethics committee of Institute of Neuropsychiatry. All participants provided written informed consent (Trial Registration No. UMIN000024461; umin.ac.jp/ctr). Ethical approval: This study was approved by the ethics committee of Institute of Neuropsychiatry. All participants provided written informed consent (Trial Registration No. UMIN000024461; umin.ac.jp/ctr)."